PTC Therapeutics, Inc.
PTCT
$50.57
$1.653.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 96.00% | 91.12% | -13.97% | 12.84% | 9.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.00% | 91.12% | -13.97% | 12.84% | 9.98% |
| Cost of Revenue | -7.16% | -10.83% | -19.15% | -23.03% | -23.41% |
| Gross Profit | 304.88% | 334.42% | 4.44% | 1,659.64% | 836.32% |
| SG&A Expenses | 8.14% | -3.23% | -9.51% | -16.18% | -13.86% |
| Depreciation & Amortization | -92.53% | -94.46% | -72.72% | -25.72% | 23.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.82% | -25.08% | -25.92% | -21.58% | -15.20% |
| Operating Income | 550.40% | 410.40% | 58.00% | 75.10% | 59.05% |
| Income Before Tax | 234.82% | 200.87% | 47.84% | 41.62% | 28.33% |
| Income Tax Expenses | 353.65% | 184.93% | 100.25% | 131.85% | 79.60% |
| Earnings from Continuing Operations | 231.21% | 202.70% | 42.02% | 29.38% | 22.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 231.21% | 202.70% | 42.02% | 29.38% | 22.41% |
| EBIT | 550.40% | 410.40% | 58.00% | 75.10% | 59.05% |
| EBITDA | 6,935.62% | 3,029.36% | 36.99% | 106.86% | 104.20% |
| EPS Basic | 227.01% | 198.37% | 43.52% | 31.42% | 25.00% |
| Normalized Basic EPS | 325.77% | 284.26% | 54.49% | 53.66% | 40.31% |
| EPS Diluted | 210.28% | 184.63% | 43.48% | 31.43% | 25.05% |
| Normalized Diluted EPS | 300.70% | 263.64% | 54.49% | 53.66% | 40.31% |
| Average Basic Shares Outstanding | 2.07% | 2.28% | 2.68% | 3.08% | 3.87% |
| Average Diluted Shares Outstanding | 4.79% | 5.01% | 2.68% | 3.08% | 3.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |